Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.
驻足于神经遗传医学进步的生物技术公司Voyager Therapeutics, Inc. (纳斯达克代码：VYGR)宣布将于2024年6月20日下午1:35 ET，在TD Cowen遗传医学和RNA峰会上参加炉边交谈，在2024年6月27日上午7:00 ET，在H.C. Wainwright第五届虚拟神经视角年会上参加炉边交谈。
Webcasts of the presentations may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcasts will be archived on the Company's website for at least 30 days.
演示文稿的网络直播可以从Voyager网站的投资者部分获得：ir.voyagertherapeutics.com网络直播的重播将被归档在公司网站上至少30天。
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
关于voyager therapeutics
纳斯达克：VYGR Voyager Therapeutics是一家专注于利用人类基因改变神经系统疾病进展和最终治愈的生物技术公司。我们的产线包括阿尔茨海默病、肌萎缩侧索硬化症（ALS）、帕金森病和多种其他中枢神经系统疾病的计划。我们的许多计划都源于我们的TRACER AAV外壳发现平台，我们已经用它来生成新颖的外壳并识别相关的受体，以可能实现静脉注射遗传药物的高脑穿透率。我们的一些计划是完全自有的，一些正在与合作伙伴合作推进，包括Alexion、阿斯利康罕见病、Novartis Pharma AG、Neurocrine Biosciences、Sangamo Therapeutics等。欲了解更多信息，请访问：www.voyagertherapeutics.com.
Voyager Therapeutics is a registered trademark, and TRACER is a trademark, of Voyager Therapeutics, Inc.
voyager therapeutics是voyager therapeutics, inc.的注册商标，而TRACER则是该公司的商标。
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
联系方式
Trista Morrison，NACD.DC，tmorrison@vygr.com
投资者：Adam Bero，博士，abero@kendallir.com
媒体：Brooke Shenkin，brooke@scientpr.com
Source: Voyager Therapeutics, Inc.
资料来源：Voyager Therapeutics, Inc.